A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Conditions : Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer Interventions : Drug: Patritumab deruxtecan; Drug: Trastuzumab deruxtecan Sponsors…
Read the full article3d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Pooled analysis of over 120 clinical trials finds no increased cardiovascular risk with sildenafil (Viagra)
pubmed.ncbi.nlm.nih.gov·1h agoThe future of US psychedelic medicine is carved out by the FDA
refractor.io·2h ago
The future of US psychedelic medicine is carved out by the FDA
refractor.io·2h ago
Umoja Receives FDA IND Clearance for CD22-Directed In Vivo CAR-T Therapy
PackGene Biotech·3h ago
Johnson & Johnson Discontinues JNJ-1887 Gene Therapy Program for Geographic Atrophy
PackGene Biotech·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.